Klaus Bosslet, has led cancer research projects and cancer R&D teams for more than 30 years. Currently, he is the “Site Head of Discovery Oncology, Roche Innovation Center Penzberg, Germany, Roche Oncology Pharmaceutical Research & Early Development Division (pRED).
Klaus joined Roche in January 2011, after serving as MedImmune’s Vice President of Oncology Research (U.S. and U.K.), where he managed one of the top biologics oncology portfolios in the industry.
In 1998, Klaus Bosslet began working at Schering AG as head of the Experimental Oncology Department. In 2001, he became global head of the company’s corporate research business area in oncology, making him responsible for preclinical research and development of therapeutic projects. In 2006, until he left the company in 2008, Klaus Bosslet built and managed the oncology research team at Bayer Schering Pharma, which included all small molecule and antibody projects in 3 distinct disease mechanisms. Earlier in his career, he headed R&D departments at ProVirus Inc./ProNeuron Inc., Hoechst-Marion-Roussel and Behringwerke AG. He did his post-doctoral work at the German Cancer Research Center in the field of tumor immunology.